ARTBIO Secures $132 Million in Series B Funding to Propel Alpha Radioligand Therapies
Deal News | Jul 29, 2025 | Goodwin
ARTBIO, a clinical-stage radiopharmaceutical company, secured $132 million in Series B financing to advance its alpha radioligand therapies. The financing is co-led by new investors Sofinnova Investments and B Capital, alongside previous investor contributors, including a life sciences dedicated investment fund. Additional support came from existing backers like F-Prime, Omega Funds, and Third Rock Ventures, as well as newcomers such as Qatar Investment Authority and Alexandria Venture Investments. The funds will facilitate ARTBIO's development of its ARTs, including its lead program, AB001, through Phase II clinical trials and enable supply chain expansion. ARTBIO specializes in creating a novel class of therapies by selecting optimal isotopes and tumor-specific targets using its proprietary AlphaDirect technology. The consultants from Goodwin, led by Catherine Magazu and other key experts, provided advisory services for this financing round.
Sectors
- Biotechnology and Life Sciences
- Private Equity and Venture Capital
- Healthcare and Pharmaceuticals
Geography
- United States – The article includes information about several US-based investors and advisories involved in the funding round.
- Norway – ARTBIO's scientific development is rooted in pioneering work conducted at the University of Oslo and Norway's Radium Hospital.
Industry
- Biotechnology and Life Sciences – The article revolves around ARTBIO, a company involved in the development of new cancer treatment methodologies using radiopharmaceuticals.
- Private Equity and Venture Capital – The funding round for ARTBIO involves substantial contributions from private equity firms and venture capital investors.
- Healthcare and Pharmaceuticals – With a focus on advancing ARTBIO's clinical trials and therapies for cancer treatment, the article involves the healthcare sector.
Financials
- $132 million – The total amount of Series B financing raised by ARTBIO.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ARTBIO | Target Company | Company | ARTBIO is a clinical-stage radiopharmaceutical company focusing on developing alpha radioligand therapies for cancer treatment. |
| Goodwin | Legal Advisor | Company | Goodwin is a law firm that provided advisory services for ARTBIO's $132 million Series B financing. |
| Sofinnova Investments | Investor | Company | A lead investor in ARTBIO's Series B financing, Sofinnova Investments is a venture capital firm investing in life sciences. |
| B Capital | Investor | Company | B Capital is a venture capital firm that co-led the Series B funding round for ARTBIO. |
| F-Prime | Investor | Company | A previous investor in ARTBIO's operations, continuing to support the company's development. |
| Omega Funds | Investor | Company | Omega Funds is an existing investor in ARTBIO's program, contributing to the Series B round. |
| Third Rock Ventures | Investor | Company | Third Rock Ventures continues its investment in ARTBIO by participating in the latest funding round. |
| Qatar Investment Authority | Investor | Company | New to ARTBIO's investment list, Qatar Investment Authority contributed to the Series B funding. |
| Alexandria Venture Investments | Investor | Company | A new investor in ARTBIO's funding, Alexandria Venture Investments participated in the Series B round. |
| University of Oslo | Academic Institution | Government | ARTBIO's technological development is based on pioneering work conducted at the University of Oslo. |
| Norway's Radium Hospital | Institute | Government | Contributed to the scientific origins of ARTBIO's cancer therapies. |
| Catherine Magazu | Advisor | Person | A member of Goodwin's team that advised ARTBIO on its Series B financing. |
| Kingsley Taft | Advisor | Person | Part of the Goodwin team advising ARTBIO. |
| Kristen McCarthy | Advisor | Person | A Goodwin team member who advised ARTBIO on its latest funding. |
| Daniela Sanchez | Advisor | Person | Contributed to Goodwin's advisory role for ARTBIO's Series B round. |